Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 13, Number 8—August 2007
Letter

Threat to Cefixime Treatment for Gonorrhea

Shigeaki Yokoi*, Takashi Deguchi*Comments to Author , Tomomi Ozawa*, Mitsuru Yasuda*, Shin-ichi Ito*, Yasuaki Kubota†, Masayoshi Tamaki†, and Shin-ichi Maeda†
Author affiliations: *Gifu University, Gifu, Japan; †Toyota Memorial Hospital, Toyota, Japan;

Main Article

Table

Antimicrobial drug susceptibilities of clinical isolates of Neisseria gonorrhoeae from patients with gonococcal urethritis treated unsuccessfully with a 3-day cefixime regimen*

Patient MIC (μg/mL)
Isolate PCG TET CFX CFD CDZ CTX LVF AZM SPC
1 Pre-Tx 4 2 0.5 1 0.125 0.125 16 0.25 16
Post-Tx 4 2 0.5 1 0.125 0.125 16 0.125 32
2 Pre-Tx 8 4 0.5 1 0.25 0.5 8 0.5 32
Post-Tx 8 2 0.5 1 0.125 0.25 8 0.5 16
3 Pre-Tx 4 2 1 2 0.25 0.125 16 0.25 16
Post-Tx 4 2 1 2 0.25 0.125 16 0.25 16
4 Pre-Tx 4 1 1 2 0.25 0.25 16 0.125 16
Post-Tx 4 2 1 2 0.25 0.25 16 0.25 32

*PCG, penicillin G; TET, tetracycline; CFX, cefixime; CFD, cefdinir; CDZ, cefodizime; CTX, ceftriaxone; LVF, levofloxacin; AZM, azithromycin; SPC, spectinomycin; Pre-Tx, isolate recovered before cefixime treatment; Post-Tx, isolate recovered after cefixime treatment, i.e., before ceftriaxone treatment.

Main Article

Page created: June 30, 2010
Page updated: June 30, 2010
Page reviewed: June 30, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external